{"id":344919,"date":"2025-08-14T22:02:18","date_gmt":"2025-08-14T22:02:18","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/344919\/"},"modified":"2025-08-14T22:02:18","modified_gmt":"2025-08-14T22:02:18","slug":"lilly-says-it-will-raise-drug-prices-in-europe-responding-to-trump-threats","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/344919\/","title":{"rendered":"Lilly says it will raise drug prices in Europe, responding to Trump threats"},"content":{"rendered":"

Eli Lilly on Thursday responded to a Trump administration plan to lower U.S. drug costs by issuing a statement<\/a> claiming it will raise prices in European countries to \u201calign\u201d them with the costs paid \u201cacross developed countries.\u201d<\/p>\n

The statement, which wasn\u2019t attributed to any specific Lilly executive, said the effort includes an agreement with the U.K. government to hike the price of the company\u2019s blockbuster diabetes medicine Mounjaro \u201cwhile maintaining access\u201d for people with the disease.<\/p>\n

Lilly didn\u2019t commit to cutting U.S. prices. But it did say that for prices to be reduced in the U.S., the amounts \u201cpaid by governments and health systems need to increase in other developed markets like Europe.” The company is working with other, unspecified governments and expects to make \u201cany necessary pricing adjustments\u201d by Sept. 1.<\/p>\n

Lilly didn\u2019t specify how it will raise prices in those countries \u2014 many of which have nationalized healthcare systems that negotiate drug costs for their entire population \u2014 without affecting access. It also didn\u2019t reveal whether the planned hikes would be tied to a drug\u2019s list price or the confidential rebate deals<\/a> cut between drugmakers and national customers.<\/p>\n

The statement also pointed out the difficulty of lowering prices in the U.S. because of the healthcare system\u2019s structure.<\/p>\n

\u201cThe U.S. system is complex and opaque, with multiple cross subsidies, abuse of government programs like 340B, and insurance cost-sharing burdens for patients,\u201d Lilly said.<\/p>\n

Through an executive order signed in May<\/a>, President Donald Trump aims to link the price paid for drugs in the U.S. to the lowest price paid in other high-income countries. This \u201cmost favored nation\u201d policy is also meant to spur price negotiations between the federal government and companies, as well as to push drugmakers to establish new ways to distribute medicines to patients at a reduced cost.<\/p>\n

Letters the administration sent to executives at 17 drug companies<\/a> two weeks ago redoubled that effort while vaguely warning of consequences for companies that don\u2019t comply.<\/p>\n

The \u201cmost favored nation\u201d policy has come alongside the threat of tariffs on pharmaceuticals<\/a>, which has spurred many large drugmakers \u2014\u00a0Lilly among them \u2014 to promise to invest billions of dollars in U.S. drug manufacturing.<\/p>\n

In its statement Thursday, Lilly reiterated its objections to pharmaceutical levies, arguing they\u2019d \u201craise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing.\u201d<\/p>\n

\u201cWe urge the administration and Congress to prioritize strategic incentives that strengthen U.S. manufacturing and supply\u2011chain resilience without sacrificing access, affordability, innovation, or American leadership,\u201d Lilly said.<\/p>\n","protected":false},"excerpt":{"rendered":"Eli Lilly on Thursday responded to a Trump administration plan to lower U.S. drug costs by issuing a…\n","protected":false},"author":2,"featured_media":344920,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5174],"tags":[2000,299,5187],"class_list":{"0":"post-344919","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-eu","8":"tag-eu","9":"tag-europe","10":"tag-european"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115029379936868683","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/344919","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=344919"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/344919\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/344920"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=344919"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=344919"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=344919"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}